NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel ...
Data demonstrates neflamapimod treatment led to significant reductions in plasma glial fibrillary acidic protein ( GFAP), a key marker of neuroinflammation-associated neurodegeneration, and increased ...
Understanding the shape or morphology of neurons and mapping the tree-like branches via which they receive signals from other ...
MDA’s partnership in research includes collaborative research grants with the ALS Network, Cure ADSSL1, Coalition to Cure ...
FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8Biomarker improvements are strongly associated with longer survival, ...
News-Medical.Net on MSN
Global analysis shows rising burden of ALS and motor neuron diseases
Amyotrophic lateral sclerosis (ALS) and other motor neuron diseases (MNDs) are major global causes of death. However, their ...
Dementia is a highly prevalent condition, affecting 57 million people worldwide, with nearly 10 million new cases each year, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback